
AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own DRDGOLD, you really have to believe in its niche as a high-margin, tailings-focused South African gold producer that can keep turning volatile operating conditions into solid cash generation and dividends. The recent FTSE All-World Index inclusion should modestly sharpen that story in the short term by widening the shareholder base and potentially improving liquidity, especially after a year where earnings forecasts were revised upward despite weather-related production setbacks. That combination may reinforce existing catalysts such as strong recent profitability, a history of returning cash to shareholders, and perceived value relative to peers, rather than fundamentally changing them. At the same time, the news does not remove core risks around production variability, cost control within the current guidance range, and the concentration in a single commodity and geography.
However, investors should not overlook how sensitive this story remains to operational disruptions.Simply Wall St Community members’ fair value estimates for DRDGOLD range from ZAR12.67 to ZAR92.60 across four views, underlining how far apart individual investors can be. Set against the recent index inclusion and evolving risk profile, this gap in expectations invites you to weigh how production volatility and concentration in gold might influence the company’s longer term prospects.
Explore 4 other fair value estimates on DRDGOLD - why the stock might be worth less than half the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com